Craig Shimasaki's guest appearances

Craig Shimasaki

Finding Genius Podcast

FutureTech Podcast

Oklahoma Venture Forum Podcast

Kurt Schmidinger

Kim Kush

Stasha Gominak

Dana Lewis

Louise Short

Clay Wright

Meir Kryger

Abraham Otero

Jules Chandler

Donny Hanjaya-Putra

Doug Thompson

Joseph Tector

Lawrence Bonassar

Kirsten Shockey

Irina Rish

OwlTail

Douglas Sorocco

Douglas Sorocco is owner of Dunlap Codding in Oklahoma City, an intellectual property attorney, PHOSITA blogger, chemist, visionary, social entrepreneur and creator of DC on Film Row. He’s also one of the volunteer co-directors of the new Oklahoma Entrepreneurship Mentoring Program (OKEMP). Modeled after MIT’s Venture Mentoring Service (MIT VMS), OKEMP matches an entrepreneur with a team of unbiased, experienced mentors.“This type of commitment is what’s been missing in Oklahoma,” he says. “OKEMP provides mentoring teams who follow entrepreneurs throughout their whole career. Because true entrepreneurs don’t stop with just one idea.”“One of the beauties of the program is that no matter where the entrepreneurs are in their life cycle, they’re getting matched up with mentors who can offer unbiased, unconflicted advice.”What mentors also offer is access to their experiences as successful entrepreneurs, delivered during regularly scheduled 90-minute meetings. “There is a curriculum,” explains Sorocco, “but it is driven by the entrepreneurs who are coming with questions and concerns.”“For example, the first entrepreneur may already have a prototype without ever looking at markets. So it’s backward! So the mentor helps identify who’s going to buy the product. Whereas the second entrepreneur may be a programmer who’s never sold anything. So the mentoring team teaches how to develop relationships that don’t seem too transactional.”“Most entrepreneurs are going to fail with their first or second company. What we need for them to do is learn along the way so that when they get to number three or four, they’re more likely to succeed.”https://creativeoklahoma.org/okemp/Interviewed by Dennis Spielman for The Golding Group.

Douglas Sorocco is owner of Dunlap Codding in Oklahoma City, an intellectual property attorney, PHOSITA blogger, chemist, visionary, social entrepreneur and creator of DC on Film Row. He’s also one of the volunteer co-directors of the new Oklahoma Entrepreneurship Mentoring Program (OKEMP). Modeled after MIT’s Venture Mentoring Service (MIT VMS), OKEMP matches an entrepreneur with a team of unbiased, experienced mentors. “This type of commitment is what’s been missing in Oklahoma,” he says. “OKEMP provides mentoring teams who follow entrepreneurs throughout their whole career. Because true entrepreneurs don’t stop with just one idea.” “One of the beauties of the program is that no matter where the entrepreneurs are in their life cycle, they’re getting matched up with mentors who can offer unbiased, unconflicted advice.” What mentors also offer is access to their experiences as successful entrepreneurs, delivered during regularly scheduled 90-minute meetings. “There is a curriculum,” explains Sorocco, “but it is driven by the entrepreneurs who are coming with questions and concerns.” “For example, the first entrepreneur may already have a prototype without ever looking at markets. So it’s backward! So the mentor helps identify who’s going to buy the product. Whereas the second entrepreneur may be a programmer who’s never sold anything. So the mentoring team teaches how to develop relationships that don’t seem too transactional.” “Most entrepreneurs are going to fail with their first or second company. What we need for them to do is learn along the way so that when they get to number three or four, they’re more likely to succeed.” <a href="https://creativeoklahoma.org/okemp/" rel="noopener nofollow" target="_blank">https://creativeoklahoma.org/okemp/</a> Interviewed by Dennis Spielman for The Golding Group.

OVF Podcast Ep24: Oklahoma Entrepreneur Mentoring Program with Douglas Sorocco & Craig Shimasaki

More than 60 million Americans have been prescribed some type of psychotropic drug; many of these Americans are children who have shown trouble focusing in school, motor or vocal ticks, obsessive-compulsive behavior, or a range of other signs of varying intensity. Doctors generally aim to treat the symptoms, but what about the underlying cause of the symptoms? And if the cause could be identified, would a psychotropic drug still be the preferred form of treatment? Craig Shimasaki, Ph.D., joins the podcast to discuss surprising new discoveries on this topic. He’s currently the CEO of Moleculera, a company that opened its doors in 2013 after five antibody targets were discovered in the central nervous systems of children who developed sudden-onset obsessive-compulsive disorder (OCD) after a strep infection. When antibodies attack our joints, we call it rheumatoid arthritis, when they attack our pancreas, we call is diabetes type I, but what do we call it when they attack our brain? According to Dr. Shimasaki and the team at Moleculera, we should call it an infection-triggered autoimmune response known as “molecular mimicry,” which applies not only to OCD but to a subset of ADHD and autism diagnoses as well. Moleculera has created a blood test that can identify specific markers which, in conjunction with a patient’s clinical signs, indicate whether or not a case of ADHD or autism has an immune-related cause. The patients who fall into this category have improved or seen total resolution of their symptoms after a course of anti-infectives and immune modulatory treatment. Over 1,200 doctors have already ordered the test, 7,600 patients have been tested, and Moleculera continues to accept blood samples from anywhere in the world.  Dr. Shimasaki offers compelling and informative insight on a range of topics, including how the treatment works and what exactly it consists of, whether or not immune dysregulation could also be involved in schizophrenia, chronic fatigue syndrome, chronic depression, and Alzheimer’s and Parkinson’s disease, and all the details of what Moleculera has in the works, such as the use of machine learning to develop a predictive algorithm for treatment efficacy, and a pharmacoeconomic model that would demonstrate the cost savings of this new method of testing for and treating neurological and psychiatric conditions. Tune in and visit www.moleculeralabs.com to learn more.

More than 60 million Americans have been prescribed some type of psychotropic drug; many of these Americans are children who have shown trouble focusing in school, motor or vocal ticks, obsessive-compulsive behavior, or a range of other signs of varying intensity. Doctors generally aim to treat the symptoms, but what about the underlying cause of the symptoms? And if the cause could be identified, would a psychotropic drug still be the preferred form of treatment? Craig Shimasaki, Ph.D., joins the podcast to discuss surprising new discoveries on this topic. He’s currently the CEO of Moleculera, a company that opened its doors in 2013 after five antibody targets were discovered in the central nervous systems of children who developed sudden-onset obsessive-compulsive disorder (OCD) after a strep infection. When antibodies attack our joints, we call it rheumatoid arthritis, when they attack our pancreas, we call is diabetes type I, but what do we call it when they attack our brain? According to Dr. Shimasaki and the team at Moleculera, we should call it an infection-triggered autoimmune response known as “molecular mimicry,” which applies not only to OCD but to a subset of ADHD and autism diagnoses as well. Moleculera has created a blood test that can identify specific markers which, in conjunction with a patient’s clinical signs, indicate whether or not a case of ADHD or autism has an immune-related cause. The patients who fall into this category have improved or seen total resolution of their symptoms after a course of anti-infectives and immune modulatory treatment. Over 1,200 doctors have already ordered the test, 7,600 patients have been tested, and Moleculera continues to accept blood samples from anywhere in the world.  Dr. Shimasaki offers compelling and informative insight on a range of topics, including how the treatment works and what exactly it consists of, whether or not immune dysregulation could also be involved in schizophrenia, chronic fatigue syndrome, chronic depression, and Alzheimer’s and Parkinson’s disease, and all the details of what Moleculera has in the works, such as the use of machine learning to develop a predictive algorithm for treatment efficacy, and a pharmacoeconomic model that would demonstrate the cost savings of this new method of testing for and treating neurological and psychiatric conditions. Tune in and visit <a href="http://www.moleculeralabs.com" rel="nofollow" target="_blank">www.moleculeralabs.com</a> to learn more.

ADHD, Autism, and OCD: A Treatment that Works by Tackling the Root Cause--Craig Shimasaki, PhD--Moleculera

More than 60 million Americans have been prescribed some type of psychotropic drug; many of these Americans are children who have shown trouble focusing in school, motor or vocal ticks, obsessive-compulsive behavior, or a range of other signs of varying intensity. Doctors generally aim to treat the symptoms, but what about the underlying cause of the symptoms? And if the cause could be identified, would a psychotropic drug still be the preferred form of treatment? Craig Shimasaki, Ph.D., joins the podcast to discuss surprising new discoveries on this topic. He’s currently the CEO of Moleculera, a company that opened its doors in 2013 after five antibody targets were discovered in the central nervous systems of children who developed sudden-onset obsessive-compulsive disorder (OCD) after a strep infection. When antibodies attack our joints, we call it rheumatoid arthritis, when they attack our pancreas, we call is diabetes type I, but what do we call it when they attack our brain? According to Dr. Shimasaki and the team at Moleculera, we should call it an infection-triggered autoimmune response known as “molecular mimicry,” which applies not only to OCD but to a subset of ADHD and autism diagnoses as well. Moleculera has created a blood test that can identify specific markers which, in conjunction with a patient’s clinical signs, indicate whether or not a case of ADHD or autism has an immune-related cause. The patients who fall into this category have improved or seen total resolution of their symptoms after a course of anti-infectives and immune modulatory treatment. Over 1,200 doctors have already ordered the test, 7,600 patients have been tested, and Moleculera continues to accept blood samples from anywhere in the world.  Dr. Shimasaki offers compelling and informative insight on a range of topics, including how the treatment works and what exactly it consists of, whether or not immune dysregulation could also be involved in schizophrenia, chronic fatigue syndrome, chronic depression, and Alzheimer’s and Parkinson’s disease, and all the details of what Moleculera has in the works, such as the use of machine learning to develop a predictive algorithm for treatment efficacy, and a pharmacoeconomic model that would demonstrate the cost savings of this new method of testing for and treating neurological and psychiatric conditions. Tune in and visit <a href="http://www.moleculeralabs.com" rel="nofollow" target="_blank">www.moleculeralabs.com</a> to learn more.